CNS Drugs

, Volume 20, Issue 3, pp 187–198

Use of Psychotropic Medications in Treating Mood Disorders during Lactation

Practical Recommendations
  • Malin Eberhard-Gran
  • Anne Eskild
  • Stein Opjordsmoen
Therapy In Practice

Abstract

Many new mothers who need antidepressant or mood-stabilising drug treatment may wish to breastfeed their infants, but are hesitant to do so because of possible harmful effects of the medication on the infant. This article reviews current data on drug excretion into breast milk and the effects on the breast-fed child, and provides recommendations for the use of the different psychotropic drugs in lactating women.

Relevant literature was identified through systematic searches of MEDLINE, EMBASE and the Science Citation Index Expanded (ISI) from 1966 to February 2005. The present knowledge is based on the accumulation of case studies. No randomised controlled trials in breast-fed infants have been performed and there is a lack of long-term follow-up studies.

Use of SSRIs and TCAs (except doxepin) is compatible with breastfeeding. However, if treatment with an SSRI is started in the postpartum period, fluoxetine and citalopram may not be drugs of first choice. With regard to other antidepressants, such as venlafaxine, trazodone, mirtazapine, reboxetine, moclobemide and other MAOIs, very little knowledge exists. Breastfeeding should be avoided while using lithium. Carbamazepine and sodium valproate (valproic acid) are generally better tolerated by the breast-fed infant than lithium. Data on lamotrigine are still sparse. Knowledge is also scarce on the novel antipsychotics and thus recommendations in lactating women cannot be made for these agents. It is unwise to expose infants unnecessarily to drugs that may have severe adverse effects. As such, clozapine should probably be avoided because of the risk of agranulocytosis.

Our knowledge of the impact of drug exposure through breast milk is still limited. Infant drug exposure is, however, generally higher during pregnancy through placental passage than through breast milk. Despite the low dosage transfered to the infant through breast milk, premature infants and infants with neonatal diseases or inherited disturbances in metabolism may be vulnerable to such exposure.

References

  1. 1.
    Watson JP, Elliot SA, Rugg AJ. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 1984; 144: 453–62PubMedCrossRefGoogle Scholar
  2. 2.
    Kumar R, Robson KM. A prospective study of emotional disorders in child-bearing women. Br J Psychiatry 1984; 144: 35–47PubMedCrossRefGoogle Scholar
  3. 3.
    Hendrick V, Smith LM, Hwang S, et al. Weight gain in breastfed infants of mothers taking antidepressant medications. J Clin Psychiatry 2003; 64: 410–2PubMedCrossRefGoogle Scholar
  4. 4.
    Moore G, Cohn J, Campbell S. Infant affective responses to mother’s still face at 6 months differentially predict externalizing and internalizing behaviors at 18 months. Dev Psychol 2001; 37: 706–14PubMedCrossRefGoogle Scholar
  5. 5.
    Sinclair D, Murray L. Effects of postnatal depression on children’s adjustment to school. Br J Psychiatry 1998; 172: 58–63PubMedCrossRefGoogle Scholar
  6. 6.
    Murray L, Sinclair D, Cooper PJ, et al. The socioemotional development of 5-year-old children of postnatally depressed mothers. J Child Psychol Psychiatry 1999; 40: 1259–71PubMedCrossRefGoogle Scholar
  7. 7.
    Weinberg M, Tronick E. The impact of maternal psychiatric illness on infant development. J Clin Psychiatry 1998; 59: 53–61PubMedGoogle Scholar
  8. 8.
    Friel JK, Martin SM, Langdon M, et al. Milk from mothers of both premature and full-term infants provides better antioxidant protection than does infant formula. Pediatr Res 2002; 51: 612–8PubMedCrossRefGoogle Scholar
  9. 9.
    A Joint WHO/UNICEF Statement. Protecting, promoting and supporting breastfeeding: the special role of maternity services. Geneva: WHO, 1989Google Scholar
  10. 10.
    American Academy of Pediatrics. Breastfeeding and the use of human milk. Pediatrics 1997; 100: 1035–9CrossRefGoogle Scholar
  11. 11.
    Golding J, Emmett P, Rogers I. Gastroenteritis, diarrhoea and breast feeding. Early Hum Dev 1997; 49 Suppl.: s83–103PubMedCrossRefGoogle Scholar
  12. 12.
    van Odijk J, Kull I, Borres M, et al. Breast feeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations. Allergy 2003; 58: 833–43PubMedCrossRefGoogle Scholar
  13. 13.
    Foster S, Slade P, Wilson K. Body image, maternal fetal attachment, and breast feeding. J Psychosom Res 1996; 41: 181–4PubMedCrossRefGoogle Scholar
  14. 14.
    Uvnas-Moberg K. Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology 1998; 23: 819–35PubMedCrossRefGoogle Scholar
  15. 15.
    Liestøl K, Rosenberg M, Walloe L. Breast-feeding practice in Norway 1860–1984. J Biosoc Sci 1988; 20: 45–58PubMedGoogle Scholar
  16. 16.
    Ryan AS, Wenjun Z, Acosta A. Breastfeeding continues to increase into the new millennium. Pediatrics 2002; 110: 1103–9PubMedCrossRefGoogle Scholar
  17. 17.
    Newport D, Wilcox M, Stowe Z. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001; 25: 177–90PubMedCrossRefGoogle Scholar
  18. 18.
    Wisner K, Perel J, Findling R. Antidepressant treatment during breast-feeding. Am J Psychiatry 1996; 153: 1132–7PubMedGoogle Scholar
  19. 19.
    Spigset O, Hagg S. Excretion of psychotropic drugs into breastmilk; pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9(2): 111–34CrossRefGoogle Scholar
  20. 20.
    Misri S, Kostaras X. Benefits and risks to mother and infant of drug treatment for postnatal depression. Drug Saf 2002; 25: 903–11PubMedCrossRefGoogle Scholar
  21. 21.
    Wisner K, Parry B, Piontek C. Postpartum depression. N Engl J Med 2002; 347: 194–9PubMedCrossRefGoogle Scholar
  22. 22.
    Yoshida K, Smith B, Kumar R. Psychotropic drugs in mothers’ milk: a comprehensive review of assay methods, pharmacokinetics and safety of breast-feeding. J Psychopharmacol 1999; 13: 64–80PubMedCrossRefGoogle Scholar
  23. 23.
    Burt V, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001; 158: 1001–9PubMedCrossRefGoogle Scholar
  24. 24.
    Dodd S, Buist A, Norman T. Antidepressants and breast-feeding. Paediatr Drugs 2000; 2: 183–92PubMedCrossRefGoogle Scholar
  25. 25.
    Hagg S, Spigset O. Anticonvulsant use during lactation. Drug Saf 2000; 22: 425–40PubMedCrossRefGoogle Scholar
  26. 26.
    Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159: 1667–73PubMedCrossRefGoogle Scholar
  27. 27.
    Cox JL, Murray D, Chapman G. A controlled study of the onset, duration and prevalence of postnatal depression. Br J Psychiatry 1993; 163: 27–31PubMedCrossRefGoogle Scholar
  28. 28.
    O MW, Swain AM. Rates and risk of postpartum depression: a meta-analysis. Int Rev Psychiatry 1996; 8: 37–54CrossRefGoogle Scholar
  29. 29.
    Paykel E, Emms E, Fletcher J, et al. Life events and social support in puerperal depression. Br J Psychiatry 1980; 136: 339–46PubMedCrossRefGoogle Scholar
  30. 30.
    Eberhard-Gran M, Eskild A, Tambs K, et al. Depression in postpartum and non-postpartum women: prevalence and risk factors. Acta Psychiatr Scand 2002; 105: 426–33CrossRefGoogle Scholar
  31. 31.
    Eberhard-Gran M, Eskild A, Tambs K, et al. Review of validation studies of the Edinburgh Postnatal Depression Scale. Acta Psychiatr Scand 2001; 104: 243–9PubMedCrossRefGoogle Scholar
  32. 32.
    Eberhard-Gran M, Tambs K, Opjordsmoen S, et al. Depression during pregnancy and after delivery: a repeated measurement study. J Psychosom Obstet Gynecol 2004; 25: 15–21CrossRefGoogle Scholar
  33. 33.
    Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257–60PubMedCrossRefGoogle Scholar
  34. 34.
    O’Hara MW, Zekoski EM, Philipps LH, et al. Controlled prospective study of postpartum mood disorders: comparison of childbearing and nonchildbearing women. J Abnorm Psychol 1990; 99: 3–15PubMedCrossRefGoogle Scholar
  35. 35.
    Johanson R, Chapman G, Murray L, et al. The North Staffordshire Maternity Hospital prospective study of pregnancy-associated depression. J Psychosom Obstet Gynaecol 2000; 21: 93–7PubMedCrossRefGoogle Scholar
  36. 36.
    Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251–5PubMedCrossRefGoogle Scholar
  37. 37.
    Eberhard-Gran M, Tambs K, Opjordsmoen S, et al. A comparison of anxiety and depressive symptomatology in puerperal and non-puerperal women. Soc Psychiatry Psychiatr Epidemiol 2003; 38: 551–6PubMedCrossRefGoogle Scholar
  38. 38.
    Klein M, Essex MJ. Pregnant or depressed? The effect of overlap between symptoms of depression and somatic complaints of pregnancy on rates of major depression during second trimester. Depression 1994; 2: 1994–5CrossRefGoogle Scholar
  39. 39.
    O’Hara MW, Neunaber DJ, Zekoski EM. Prospective study of postpartum depression: prevalence, course, and predictive factors. J Abnorm Psychol 1984; 93: 158–71PubMedCrossRefGoogle Scholar
  40. 40.
    Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150: 782–6PubMedCrossRefGoogle Scholar
  41. 41.
    Brockington I. Postpartum psychiatric disorders. Lancet 2004; 363: 303–10PubMedCrossRefGoogle Scholar
  42. 42.
    O’Hara MW, Zekoski E. Postpartum depression: a comprehensive review. In: Kumar R, Brockington I, editors. Motherhood and mental illness. London: Wright, 1988: 17–63Google Scholar
  43. 43.
    First MB, Spitzer RL, Gibbon M, et al. Structural clinical interview for DSM-IV axis I disorders: patient edition (SCID I/P, version 2.0). New York: New York State Psychiatric Institute, Biometric Research Department, 1995Google Scholar
  44. 44.
    Emerson C. Thyroid diseases during and after pregnancy. In: Braverman J, editor. Werner and Ingbar’s the thyroid. Philadelphia (PA): Lippincott Company, 1991: 1263–79Google Scholar
  45. 45.
    Learoyd D, Fung H, McGregor A. Postpartum thyroid dysfunction. Thyroid 1992; 2: 73–80PubMedCrossRefGoogle Scholar
  46. 46.
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: 4th ed. Washington (DC): American Psychiatric Press, 1994Google Scholar
  47. 47.
    Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143–51PubMedCrossRefGoogle Scholar
  48. 48.
    Brockington I, Cernick K, Schofield E, et al. Puerperal psychosis. Arch Gen Psychiatry 1981; 38: 829–33PubMedCrossRefGoogle Scholar
  49. 49.
    Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987; 150: 662–73PubMedCrossRefGoogle Scholar
  50. 50.
    Bennazzi F. Mood patterns and classification in bipolar disorder. Curr Opin Psychiatry 2006; 19: 1–8CrossRefGoogle Scholar
  51. 51.
    Breitzka R, Sandritter T, Hatzopoulus F. Principles of drug transfer into breastmilk and drug disposition in the nursing infant. J Hum Lact 1997; 13: 155–8PubMedCrossRefGoogle Scholar
  52. 52.
    Jensen P, Olesen O, Bertelsen A, et al. Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant. Ther Drug Monit 1997; 19: 236–9PubMedCrossRefGoogle Scholar
  53. 53.
    Kacew S. Adverse effects of drugs and chemicals in breast milk on the nursing infant. J Clin Pharmacol 1993; 33: 213–21PubMedGoogle Scholar
  54. 54.
    Anderson PO, Pochop SL, Manoguerra AS. Adverse drug reactions in breastfed infants: less than imagined. Clin Pediatr 2003; 42: 325–40CrossRefGoogle Scholar
  55. 55.
    Suri R, Stowe ZN, Hendrick V, et al. Estimates of nursing infant daily dose of fluoxetine through breast milk. Biol Psychiatry 2002; 52: 446–51PubMedCrossRefGoogle Scholar
  56. 56.
    Stokes P, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19: 1135–250PubMedCrossRefGoogle Scholar
  57. 57.
    Kristensen J, Ilett K, Hackett L, et al. Distribution and excretion of fluoxetine and norfluoxetine in human milk. Br J Clin Pharmacol 1999; 48: 521–7PubMedCrossRefGoogle Scholar
  58. 58.
    Taddio A, Ito S, Koren G. Excretion of fluoxetine and its metabolite, norfluoxetine, in human breastmilk. J Clin Pharmacol 1996; 36: 42–7PubMedGoogle Scholar
  59. 59.
    Isenberg KE. Excretion of fluoxetine in human breast milk [letter]. J Clin Psychiatry 1990; 51: 169PubMedGoogle Scholar
  60. 60.
    Burch K, Wells B. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992; 89: 676–7PubMedGoogle Scholar
  61. 61.
    Yoshida K, Smith B, Kumar R. Fluvoxamine in breast-milk and infant development. Br J Clin Pharmacol 1997; 44: 210–1PubMedGoogle Scholar
  62. 62.
    Wright S, Dawling S, Ashford J. Excretion of fluvoxamine in breast milk [letter]. Br J Clin Pharmacol 1991; 31: 209PubMedCrossRefGoogle Scholar
  63. 63.
    Begg E, Duffull SB, Saunders DA, et al. Paroxetine in human milk. Br J Clin Pharmacol 1999; 48: 142–7PubMedCrossRefGoogle Scholar
  64. 64.
    Stowe Z, Cohen L, Hostetter A, et al. Paroxetine in human breast milk and nursing infants. Am J Psychiatry 2000; 157: 185–9PubMedCrossRefGoogle Scholar
  65. 65.
    Misri S, Kim J, Riggs K, et al. Paroxetine levels in postpartum depressed women, breast milk, and infant serum. J Clin Psychiatry 2000; 61: 828–32PubMedCrossRefGoogle Scholar
  66. 66.
    Ohman R, Hagg S, Carleborg L, et al. Excretion of paroxetine into breast milk. J Clin Psychiatry 1999; 60: 519–23PubMedCrossRefGoogle Scholar
  67. 67.
    Spigset O, Carleborg L. Paroxetine level in breast milk [letter]. J Clin Psychiatry 1996; 57: 39PubMedGoogle Scholar
  68. 68.
    Rampono J, Kristensen J, Hackett L, et al. Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants. Br J Clin Pharmacology 2000; 50: 263–8CrossRefGoogle Scholar
  69. 69.
    Schmidt K, Olesen O, Jensen P. Citalopram and breastfeeding: serum concentration and side effects in the infant. Biol Psychiatry 2000; 47: 164–5PubMedCrossRefGoogle Scholar
  70. 70.
    Spigset O, Carleborg L, Ohman R, et al. Excretion of citalopram in breast milk. Br J Clin Pharmacol 1997; 44: 236–9Google Scholar
  71. 71.
    Kristensen J, Ilett K, Dusci L, et al. Distribution and excretion of sertraline and N-desmethylsertraline in human milk. Br J Clin Pharmacol 1998; 45: 453–7PubMedCrossRefGoogle Scholar
  72. 72.
    Stowe Z, Owens M, Landry J, et al. Sertraline and desmethylser-traline in human breast milk and nursing infants. Am J Psychiatry 1997; 154: 1255–60PubMedGoogle Scholar
  73. 73.
    Hagg S, Granberg K, Carleborg L. Excretion of fluvoxamine into breast milk. Br J Clin Pharmacol 2000; 49: 283–8Google Scholar
  74. 74.
    Kristensen J, Hackett L, Kohan R, et al. The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants. J Hum Lact 2002; 18: 139–43PubMedCrossRefGoogle Scholar
  75. 75.
    Altamura A, Moro A, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201–14PubMedCrossRefGoogle Scholar
  76. 76.
    Brent N, Wisner KL. Fluoxetine and carbamazepine concentrations in a nursing mother/infant pair. Clin Pediatr 1998; 37: 41 -4CrossRefGoogle Scholar
  77. 77.
    Lester B, Cucca J, Andreozzi B, et al. Possible association between fluoxetine hydrochloride and colic in an infant. J Am Acad Child Adolesc Psychiatry 1993; 32: 1253–5PubMedCrossRefGoogle Scholar
  78. 78.
    Hale TW, Shum S, Grossberg M. Fluoxetine toxicity in a breastfed infant. Clin Pediatr 2005; 40: 681–4CrossRefGoogle Scholar
  79. 79.
    Chambers C, Anderson P, Thomas R, et al. Weight gain in infants breastfed by mothers who take fluoxetine. Pediatrics 1999; 104: e61PubMedCrossRefGoogle Scholar
  80. 80.
    Yoshida K, Smith B, Craggs M, et al. Fluoxetine in breast-milk and developmental outcome of breast-fed infants. Br J Psychiatry 1998; 172: 175–9PubMedCrossRefGoogle Scholar
  81. 81.
    Birnbaum C, Cohen L, Bailey J, et al. Serum concentrations of antidepressants and benzodiazepines in nursing infants: a case series. Pediatrics 1999; 104: e11PubMedCrossRefGoogle Scholar
  82. 82.
    Berle JO, Steen VM, Aamo TO, et al. Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes. J Clin Psychiatry 2004; 65: 1228–34PubMedCrossRefGoogle Scholar
  83. 83.
    Hendrick V, Fukuchi A, Altshuler L, et al. Use of sertraline, paroxetine and fluvoxamine by nursing women. Br J Psychiatry 2001; 179: 163–6PubMedCrossRefGoogle Scholar
  84. 84.
    Altshuler L, Burt V, McMullen M, et al. Breastfeeding and sertraline: a 24-hour analysis. J Clin Psychiatry 1995; 56: 243–5PubMedGoogle Scholar
  85. 85.
    Epperson C, Anderson G, McDougle C, et al. Sertraline and breastfeeding. N Engl J Med 1997; 336: 1189–90PubMedCrossRefGoogle Scholar
  86. 86.
    Mammen O, Perel J, Rudolph G, et al. Sertraline and norser-traline levels in three breastfed infants. J Clin Psychiatry 1997; 58: 100–3PubMedCrossRefGoogle Scholar
  87. 87.
    Wisner K, Perel J, Blumer J. Serum sertraline and N-desmethyl-sertraline levels in breast-feeding mother-infant pairs. Am J Psychiatry 1998; 155: 690–2PubMedGoogle Scholar
  88. 88.
    Dodd S, Stocky A, Buist A, et al. Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 2000; 15: 261–4CrossRefGoogle Scholar
  89. 89.
    Stowe Z, Hostetter A, Owens M, et al. The pharmacokinetics of sertraline excretion into human breast milk: determinants of infant serum concentration. J Clin Psychiatry 2003; 64: 73–80PubMedCrossRefGoogle Scholar
  90. 90.
    Epperson N, Czarkowski KA, Ward-O’Brien D, et al. Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs. Am J Psychiatry 2001; 158: 1631–7PubMedCrossRefGoogle Scholar
  91. 91.
    Piontek C, Wisner K, Perel J, et al. Serum fluvoxamine levels in breastfed infants. J Clin Psychiatry 2001; 62: 111–3PubMedCrossRefGoogle Scholar
  92. 92.
    Brixen-Rasmussen L, Halgrener J, Jorgensen A. Amitriptyline and nortriptyline excretion in human breast milk. Psychopharmacology 1982; 76: 94–5PubMedCrossRefGoogle Scholar
  93. 93.
    Breyer-Pfaff U, Nill K, Entemann A, et al. Secretion of amitriptyline and metabolites into breast milk. Am J Psychiatry 1995; 152: 812–3PubMedGoogle Scholar
  94. 94.
    Wisner K, Perel J. Serum nortriptyline levels in nursing mothers and their infants. Am J Psychiatry 1991; 148: 1234–6PubMedGoogle Scholar
  95. 95.
    Wisner K, Perel J. Nortriptyline treatment of breast-feeding women [letter]. Am J Psychiatry 1996; 153: 295PubMedGoogle Scholar
  96. 96.
    Stancer H, Reed K. Desipramine and 2-hydroxydesipramine in human breast milk and the nursing infant’s serum. Am J Psychiatry 1986; 143: 1595–600Google Scholar
  97. 97.
    Schimmell M, Katz E, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29: 479–84PubMedCrossRefGoogle Scholar
  98. 98.
    Wisner K, Perel J, Foglia J. Serum clomipramine and metabolite levels in four nursing mother-infant pairs. J Clin Psychiatry 1995; 56: 17–20PubMedGoogle Scholar
  99. 99.
    Ilett K, Lebedevs T, Wojnar-Horton R, et al. The excretion of dothiepin and its primary metabolites in breast milk. Br J Clin Pharmacol 1992 Jun; 33(6): 635–9PubMedCrossRefGoogle Scholar
  100. 100.
    Matheson I, Pande H, Alertsen A. Respiratory depression caused by N-desmethyldoxepin in breast milk [letter]. Lancet 1985; II: 1124CrossRefGoogle Scholar
  101. 101.
    Kemp J, Ilett K, Booth J, et al. Excretion of doxepin and N-desmethyldoxepin in human milk. Br J Clin Pharmacol 1985; 20: 497–9PubMedCrossRefGoogle Scholar
  102. 102.
    Frey O, Scheidt P, von Brenndorff A. Adverse effects in a newborn infant breast-fed by a mother treated with doxepin. Ann Pharmacother 1999; 33: 690–3PubMedCrossRefGoogle Scholar
  103. 103.
    Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157–71PubMedCrossRefGoogle Scholar
  104. 104.
    Buist A, Janson H. Effect of exposure to dothiepin and northiaden in breast milk on child development. Br J Psychiatry 1995; 167: 370–3PubMedCrossRefGoogle Scholar
  105. 105.
    Yoshida K, Smith B, Craggs M, et al. Investigation of pharmacokinetics and of possible adverse effects in infants exposed to tricyclic antidepressants in breast-milk. J Affect Disord 1997; 43: 225–37PubMedCrossRefGoogle Scholar
  106. 106.
    Ilett K, Hackett L, Dusci L. Distribution and excretion of venlafaxine and O-desmethylvenlafaxine in human milk. Br J Clin Pharmacol 1998; 45: 459–62PubMedCrossRefGoogle Scholar
  107. 107.
    Ilett K, Kristensen J, Hackett L, et al. Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants. Br J Clin Pharmacol 2002; 53: 17–22PubMedCrossRefGoogle Scholar
  108. 108.
    Hendrick V, Altshuler L, Wertheimer A, et al. Venlafaxine and breast-feeding. Am J Psychiatry 2001; 158: 2089–90PubMedCrossRefGoogle Scholar
  109. 109.
    Verbeeck RK, Ross SG, McKenna EA. Excretion of trazodone in breast milk. Br J Clin Pharmacol 1986; 22: 367–70PubMedCrossRefGoogle Scholar
  110. 110.
    Dodd S, Buist A, Burrows G, et al. Determination of nefazodone and its pharmacologically active metabolites in human blood plasma and breastmilk by high-performance liquid chromatography. J Chromatogr B 1999; 730: 249–55CrossRefGoogle Scholar
  111. 111.
    Yapp P, Ilett K, Kristensen J, et al. Drowsiness and poor feeding in a breast-fed infant: association with nefazodone and its metabolites. Ann Pharmacother 2000; 34: 1269–72PubMedCrossRefGoogle Scholar
  112. 112.
    Pons G, Schoerlin MP, Tam YK, et al. Maclobemide excretion in human breast milk. Br J Clin Pharmacol 1990; 29: 27–31PubMedCrossRefGoogle Scholar
  113. 113.
    Patrick MJ, Tilstone WJ, Reavey P. Diazepam and breastfeeding. Lancet 1972; I: 542–3CrossRefGoogle Scholar
  114. 114.
    Wesson DR, Cambers S, Harkey M, et al. Diazepam and desmethyldiazepam in breast milk. J Psychoactive Drugs 1985; 17: 55–6PubMedCrossRefGoogle Scholar
  115. 115.
    Pons G, Francoual C, Guillet PH, et al. Zolpidem excretion in breast milk. Eur J Clin Pharmacol 1989; 37: 245–8PubMedCrossRefGoogle Scholar
  116. 116.
    Matheson I, Sande HA, Gaillot J. The excretion of zopiclone into breast milk. Br J Clin Pharmacol 1990; 30: 267–71PubMedCrossRefGoogle Scholar
  117. 117.
    Tunnessen WW, Hertz CG. Toxic effects of lithium in newborn infants: a commentary. J Pediatr 1972; 81: 804–7PubMedCrossRefGoogle Scholar
  118. 118.
    Amdsen A. Clinical features and management of lithium poisoning. Med Toxicol Adverse Drug Exp 1988; 3: 18–32CrossRefGoogle Scholar
  119. 119.
    Llewellyn A, Stowe ZN, Strader JR. The use of lithium and management of women with bipolar disorder during pregnancy and lactation. J Clin Psychiatry 1998; 59Suppl. 6: 57–64PubMedGoogle Scholar
  120. 120.
    Schou M. Lithium treatment during pregnancy, delivery, and lactation: an update. J Clin Psychiatry 1990; 51: 410–3PubMedGoogle Scholar
  121. 121.
    Pynnonen S, Kanto J, Sillanpaa M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol 1977; 41: 244–53CrossRefGoogle Scholar
  122. 122.
    Niebyl JR, Blake DA, Freeman JM, et al. Carbamazepine levels in pregnancy and lactation. Obstet Gynecol 1979; 53: 139–40PubMedGoogle Scholar
  123. 123.
    Kaneko S, Sato T, Susuki K. The levels of anticonvulsants in breast milk. Br J Clin Pharmacol 1979; 7: 624–7PubMedCrossRefGoogle Scholar
  124. 124.
    Kaneko S, Susuki K, Sato T. The problems of antiepileptic medication in the neonatal period: is breast feeding advisable. In: Janz D, editor. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 343–8Google Scholar
  125. 125.
    Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann Clin Biochem 2000; 37: 210–5PubMedCrossRefGoogle Scholar
  126. 126.
    Piontek C, Baab S, Peindl K, et al. Serum valproate levels in 6 breastfeeding mother-infant pairs. J Clin Psychiatry 2000; 61: 170–2PubMedCrossRefGoogle Scholar
  127. 127.
    Nau H, Helge H, Luck W. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites. J Pediatr 1984; 104: 627–34PubMedCrossRefGoogle Scholar
  128. 128.
    von Unruh GE, Froescher W, Hoffmann F, et al. Valproic acid in breast milk: how much is really there? Ther Drug Monit 1984; 6: 272–6CrossRefGoogle Scholar
  129. 129.
    Wisner KL, Perel JM. Serum levels of valproate and carbamazepine in breastfeeding mother-infant pairs. J Psychopharmacol 1998; 18: 167–9CrossRefGoogle Scholar
  130. 130.
    Frey B, Schubiger G, Musy JP. Transient cholestatic hepatitis in a neonate associated with carbamazepine exposure during pregnancy and breast-feeding. Eur J Pediatr 1990; 150: 136–8PubMedCrossRefGoogle Scholar
  131. 131.
    Stahl MM, Neiderud J, Vinge E. Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. J Pediatr 1997; 130: 1001–3PubMedCrossRefGoogle Scholar
  132. 132.
    Liporace J, Kao A, D’Abreu A. Concerns regarding lamotrigine and breast-feeding. Epilepsy Behav 2004; 5: 102–5PubMedCrossRefGoogle Scholar
  133. 133.
    Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709–13PubMedCrossRefGoogle Scholar
  134. 134.
    Tomson T, Ohman I, Vitols S. Lamotrigine in pregnancy and lactation: a case report. Epilepsia 1997; 38: 1039–41PubMedCrossRefGoogle Scholar
  135. 135.
    Yatham LN. Acute and maintenance treatment of bipolar mania: the role of atypical antipsychotics. Bipolar Disord 2003; 5Suppl. 2: 7–19PubMedCrossRefGoogle Scholar
  136. 136.
    Fenton C, Scott LJ. Risperidone: a review of its use in the treatment of bipolar mania. CNS Drugs 2005; 19(5): 429–44PubMedCrossRefGoogle Scholar
  137. 137.
    Barnas C, Bergant A, Hummer M, et al. Clozapine concentrations in maternal and fetal plasma, amniotic fluid and breast milk [letter]. Am J Psychiatry 1994; 151: 945PubMedGoogle Scholar
  138. 138.
    Croke S, Buist A, Hackett L, et al. Olanzapine excretion in human breast milk: estimation of infant exposure. Int J Neuropsychopharmacol 2002; 5: 243–7PubMedCrossRefGoogle Scholar
  139. 139.
    Hill RC, McIvor RJ, Wojnar-Horton R, et al. Risperidone distribution and excretion into human milk: case report and estimated infant exposure during breast-feeding. J Clin Psychopharmacol 2000; 20: 285–6PubMedCrossRefGoogle Scholar
  140. 140.
    Ilett KF, Hackett L, Kristensen J, et al. Transfer of risperidone and 9-hydroxyrisperidone into human milk. Ann Pharmacother 2004; 38: 273–6PubMedCrossRefGoogle Scholar
  141. 141.
    Goldstein D, Corbin L, Fung MC. Olanzapine-exposed pregnancies and lactation: early experiences. J Psychopharmacol 2000; 20: 399–403CrossRefGoogle Scholar
  142. 142.
    Kirchheiner J, Berghøfer A, Bolk-Weischedel D. Healthy outcome under olanzapine treatment in a pregnant woman. Pharmacotherapy 2000; 33: 78–80Google Scholar
  143. 143.
    Gardiner SJ, Kristensen J, Begg E, et al. Transfer of olanzapine into breast milk, calculation of infant drug dose, and effect on breast-fed infants. Am J Psychiatry 2003; 160: 1428–31PubMedCrossRefGoogle Scholar
  144. 144.
    Spigset O, Hägg S. Excretion of psychotropic drugs into breast milk: pharmacokinetic overview and therapeutic implications. CNS Drugs 1998; 9(2): 111–34CrossRefGoogle Scholar
  145. 145.
    Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation. Clin Pharmacol Ther 2003; 73: 330–7PubMedCrossRefGoogle Scholar
  146. 146.
    Sharma V. Pharmacotherapy of postpartum depression. Expert Opin Pharmacother 2002; 3: 1421–31PubMedCrossRefGoogle Scholar
  147. 147.
    Holden J, Sagovsky R, Cox J. Counseling in a general practice setting: a controlled study of health visitor intervention in treatment of postnatal depression. BMJ 1989; 298: 223–6PubMedCrossRefGoogle Scholar
  148. 148.
    Wickberg B, Hwang C. Counselling of postnatal depression: a controlled study on a population based Swedish sample. J Affect Disord 1996; 39: 209–16PubMedCrossRefGoogle Scholar
  149. 149.
    Dennis CL. Treatment of postpartum depression, part 2: a critical review of nonbiological interventions. J Clin Psychiatry 2004; 65: 1252–65PubMedCrossRefGoogle Scholar
  150. 150.
    Ray K, Hodnett E. Caregiver support for postpartum depression. Available in The Cochrane Library [database on disk and CD ROM]. Updated quarterly. The Cochrane Collaboration; issue 3. Oxford: Update Software, 2002Google Scholar
  151. 151.
    Misri S, Kostaras X, Fox D, et al. The impact of partner support in the treatment of postpartum depression. Can J Psychiatry 2000; 45: 554–8PubMedGoogle Scholar
  152. 152.
    MacArthur C, Winter H, Bick D, et al. Effects of redesigned community postnatal care on womens’ health 4 months after birth: a cluster randomised controlled trial. Lancet 2002; 359: 378–85PubMedCrossRefGoogle Scholar
  153. 153.
    O’Hara M, Stuart S, Gorman L, et al. Efficacy of interpersonal psychotherapy for postpartum depression. Arch Gen Psychiatry 2000; 57: 1039–45PubMedCrossRefGoogle Scholar
  154. 154.
    Klier C, Muzik M, Rosenblum K, et al. Interpersonal psychotherapy adapted for the group setting in the treatment of postpartum depression. J Psychother Pract Res 2003; 10: 124–31Google Scholar
  155. 155.
    Appleby L, Warner R, Whitton A, et al. A controlled study of fluoxetine and cognitive-behavioral counselling in the treatment of postnatal depression. BMJ 1997; 314: 932–6PubMedCrossRefGoogle Scholar
  156. 156.
    Dennis C-L, Stewart D. Treatment of postpartum depression, part 1: a critical review of biological interventions. J Clin Psychiatry 2004; 65: 1242–51PubMedCrossRefGoogle Scholar
  157. 157.
    Reed P, Sermin N, Appleby L, et al. A comparison of clinical response to electroconvulsive therapy in puerperal and non-puerperal psychoses. J Affect Disord 1999; 54: 255–60PubMedCrossRefGoogle Scholar
  158. 158.
    Pons G, Rey E, Matheson I. Excretion of psychoactive drugs into breast milk: pharmacokinetic principles and recommendations. Clin Pharmacokinet 1994; 27: 270–89PubMedCrossRefGoogle Scholar
  159. 159.
    Wretlind M. Excretion of oxazepam in breastmilk. Eur J Clin Pharmacol 1987; 33: 209–10PubMedCrossRefGoogle Scholar
  160. 160.
    Chaudron L, Jefferson J. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000; 61: 79–90PubMedCrossRefGoogle Scholar
  161. 161.
    Sharma V, Smith A, Khan M. The relationship between duration of labour, time of delivery, and puerperal psychosis. J Affect Disord 2004; 82: 215–20CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Malin Eberhard-Gran
    • 1
  • Anne Eskild
    • 1
    • 2
  • Stein Opjordsmoen
    • 3
  1. 1.Division of EpidemiologyNorwegian Institute of Public HealthNydalen, OsloNorway
  2. 2.Department of Gynaecology and ObstetricsUllevål University HospitalOsloNorway
  3. 3.Department of PsychiatryUllevål University HospitalOsloNorway

Personalised recommendations